Home Multimedia Exclusive Videos Exclusive VideosMultimedia PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape Thursday, April 21, 2016 Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here. Advertisement Recent Articles A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres? Friday, March 15, 2019 A study of patients with bone marrow failure (BMF) and short telomeres found that a conditioning regimen that eliminates radiation and DNA-alkylating agents led... The Color of Blood and “Exohematology” Friday, March 15, 2019 Spilled blood’s brilliant red color has a rich symbolic history. The crimson color chemistry of porphyrin-bound iron ions led our ancestors to equate red... Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in CML Friday, March 15, 2019 For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a... New Policy Takes Aim at “Secret” Hospital and Insurer Negotiations Friday, March 15, 2019 In a proposed rule, the U.S. Department of Health and Human Services (HHS) announced it is considering requiring U.S. hospitals and insurers to publicize... Opioid Prescriptions Down, But Pain May Be Up Friday, March 15, 2019 Since the Centers for Disease Control and Prevention (CDC) issued strict guidelines to curb inappropriate patterns of opioid prescription, the prescribing rate has declined.... Current Issue March 2019, Volume 5, Issue 4 Friday, March 1, 2019 This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.